Cancer

T-cell therapy developer, Cbio A/S Unveils 2023 Annual Report Amid Clinical Trial Preparations, Signaling Major Shift to Clinical Stage with DKK40M Financing Secured

Cleanroom operator cutting tumor tissue Picture of Cbio cleanroom operator cutting tumor tissue for T-cell therapy production SØBORG, Denmark, April…

9 months ago

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized…

9 months ago

UPDATE: Predicine Introduces PredicineCARE™ NGS Kit for Tumor Profiling

HAYWARD, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced the release of its…

9 months ago

Nurix Therapeutics Announces Proposed Public Offering

SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein…

9 months ago

Transparency Notifications from Shareholders

PRESS RELEASEREGULATED INFORMATION 11 April 2024, 06:00 pm CEST Ghent, Belgium – 11 April 2024 – Sequana Medical NV (Euronext…

9 months ago

Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care

Dublin, Ireland--(Newsfile Corp. - April 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announces that Medtronic plc…

9 months ago

Bayer and Hologic Collaborating to Deliver Contrast-Enhanced Mammography

Collaboration Includes Robust Education and Training to Support Radiologists and Imaging SpecialistsWHIPPANY, N.J.--(BUSINESS WIRE)--Bayer and Hologic, Inc. (Nasdaq: HOLX) today…

9 months ago

Lindis Blood Care to Present Top Line Results from Clinical Certification Study REMOVE with CATUVAB(R) at NATA24 Annual Symposium

HENNINGSDORF, GERMANY / ACCESSWIRE / April 11, 2024 / Lindis Blood Care, a company aiming to set a new standard…

9 months ago

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

SEATTLE, WA / ACCESSWIRE / April 11, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing…

9 months ago

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population…

9 months ago